NR 565 Week 1 Discussion Board; Pharmacogenomics (Original Post & Peer Response)

NR 565 Week 1 Discussion
 Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive
patient the nurse practitioner orders HLA-B*5701 allele genetic testing. The test
confirms that the patient carries the HLA-B*5701 allele.
 A patient is prescribed antiplatelet therapy (clopidogrel) following an acute
myocardial infarction (MI). Six months later, the patient suffers another acute MI.
The patient has been adherent to therapy and the nurse practitioner suspects
that clopidrogel may have been ineffective. How might genetic testing have been
beneficial in this case?
 Identify 2 limitations of pharmacogenomics testing. Explain.
 Identify 2 ethical concerns of using pharmacogenomics testing. Explain




Professor and class,
Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive
patient the nurse practitioner orders HLA-B*5701 allele genetic testing. The test
confirms that the patient carries the HLA-B*5701 allele.
The HLA-B*5701 is genetic testing used to determine the potential risk for severe side
effects from the antiviral medication abacavir (De Spiegelaere et al., 2015). The HLA-B
gene has an impact on how the immune system responds and recognizes various
pathogens while mediating hypersensitivity reactions (De Spiegelaere et al., 2015). If a